Review of current treatment practices for carcinoma of the head and neck

The past two decades have witnessed a paradigm shift in the treatment of squamous cell carcinoma of the head and neck. Innovation in chemotherapy, radiotherapy and surgery has led to the assimilation of these modalities into our treatment algorithms. This modern multipart treatment plan has led to improved survival; however, this has come at the cost of increased toxicity. New and future therapies will be more tumour specific and, ideally, less toxic. Current research centres on these tumour-specific therapies with the anticipation of improved survival with decreased toxicity. This article will review the standard of care, recent advances and unfulfilled needs in the treatment of squamous cell carcinoma of the head and neck.

[1]  R. Weichselbaum,et al.  Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. , 2005, International journal of radiation oncology, biology, physics.

[2]  R. Ewers,et al.  Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients. , 2005, International journal of oral and maxillofacial surgery.

[3]  D. Raben,et al.  Emerging role of EGFR-targeted therapies and radiation in head and neck cancer. , 2004, Oncology.

[4]  D. Haraf,et al.  Reirradiation of recurrent head and neck cancers with curative intent. , 2004, Seminars in oncology.

[5]  A. Paccagnella,et al.  Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. , 2004, Journal of the National Cancer Institute.

[6]  A. Forastiere Is there a new role for induction chemotherapy in the treatment of head and neck cancer? , 2004, Journal of the National Cancer Institute.

[7]  Christopher U. Jones,et al.  Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Baselga,et al.  Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Gorlia,et al.  Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Weichselbaum,et al.  Twice-daily re-irradiation of recurrent and second primary head and neck cancer with gemcitabine, paclitaxel and fluorouracil chemoradiotherapy. , 2004, Journal of Clinical Oncology.

[11]  S. Dakhil,et al.  A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5FU) in patients with advanced or recurrent squamous cell carcinoma of the head & neck (SCCHN): A Southwest Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Rojas,et al.  Management of cancer of the head and neck--a cocktail with your PORT? , 2004, The New England journal of medicine.

[13]  Jacques Bernier,et al.  Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. , 2004, The New England journal of medicine.

[14]  J. Jacobs,et al.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.

[15]  E. Vokes,et al.  The expanding role of systemic therapy in head and neck cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Caponigro,et al.  New cytotoxic and molecular-targeted therapies of head and neck tumors , 2004, Current opinion in oncology.

[17]  G. Weinstein,et al.  Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. , 2004, International journal of radiation oncology, biology, physics.

[18]  E. Vokes,et al.  Neck dissection in the combined‐modality therapy of patients with locoregionally advanced head and neck cancer , 2004, Head & neck.

[19]  N. Slevin,et al.  Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  J. Ochs Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. , 2004, International journal of radiation oncology, biology, physics.

[21]  R. Weichselbaum,et al.  Induction Chemotherapy followed by Concomitant TFHX Chemoradiotherapy with Reduced Dose Radiation in Advanced Head and Neck Cancer , 2003 .

[22]  R. Weber,et al.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. , 2003, The New England journal of medicine.

[23]  L. Rybicki,et al.  Who merits a neck dissection after definitive chemoradiotherapy for N2–N3 squamous cell head and neck cancer? , 2003, Head & neck.

[24]  L. Dawson,et al.  Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. , 2003, International journal of radiation oncology, biology, physics.

[25]  M. Atkins,et al.  Clinical Hematology and Oncology: Presentation, Diagnosis and Treatment , 2003 .

[26]  R. Mohan,et al.  Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: dosimetric results. , 2003, International journal of radiation oncology, biology, physics.

[27]  E. Vokes,et al.  Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Baselga,et al.  Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Daniel A Low,et al.  Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. , 2003, International journal of radiation oncology, biology, physics.

[30]  A. Rademaker,et al.  Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Haie-meder,et al.  Brachytherapy for T1-T2 floor-of-the-mouth cancers: the Gustave-Roussy Institute experience. , 2002, International journal of radiation oncology, biology, physics.

[32]  C. Perez,et al.  Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  P. Xia,et al.  Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. , 2001, International journal of radiation oncology, biology, physics.

[34]  S. Stringer,et al.  Carcinoma of the supraglottic larynx: Treatment results with radiotherapy alone or with planned neck dissection , 2001, Head & neck.

[35]  W. Mendenhall,et al.  T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Bourhis,et al.  Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma , 2001, Cancer.

[37]  E. Lamont,et al.  Chemotherapy in the management of squamous-cell carcinoma of the head and neck. , 2001, The Lancet. Oncology.

[38]  S. Stringer,et al.  Organ preservation with radiotherapy for T1‐T2 carcinoma of the pyriform sinus , 2001, Head & neck.

[39]  B. Murphy,et al.  Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Shin,et al.  Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Lippman,et al.  The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. , 2001, Archives of otolaryngology--head & neck surgery.

[42]  B. Coche-Déquéant,et al.  Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma , 2000, British Journal of Cancer.

[43]  R. Weichselbaum,et al.  The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. , 2000, Archives of otolaryngology--head & neck surgery.

[44]  S. Stringer,et al.  Radiation therapy for squamous cell carcinoma of the tonsillar region: a preferred alternative to surgery? , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Carvalho,et al.  Natural history of untreated head and neck cancer. , 2000, European journal of cancer.

[46]  B. Jeremic,et al.  Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial , 2000 .

[47]  J. Bourhis,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.

[48]  W. Russell,et al.  Reversible G1 Arrest Induced by Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Requires Up-regulation of p27KIP1 Independent of MAPK Activity* , 2000, The Journal of Biological Chemistry.

[49]  K. Chao,et al.  Stage I (t1 N0 M0) squamous cell carcinoma of the laryngeal glottis: Therapeutic results and voice preservation , 1999, Head & neck.

[50]  Bruce H. Haughey,et al.  Stage I (T1 N0 M0) squamous cell carcinoma of the laryngeal glottis: therapeutic results and voice preservation. , 1999 .

[51]  E K Rowinsky,et al.  Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  H. Tideman CARCINOMA of the head and neck. , 1999, Maryland state medical journal.

[53]  J. Bourhis,et al.  Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  D. Brasnu,et al.  Neo‐adjuvant chemotherapy and supracricoid partial laryngectomy with cricohyoidopexy for advanced endolaryngeal carcinoma classified as T3–T4: 5‐year oncologic results , 1998, Head & neck.

[55]  K. Ang,et al.  Precisely defining high‐risk operable head and neck tumors based on rtog #85‐03 and #88‐24: Targets for postoperative radiochemotherapy? , 1998, Head & neck.

[56]  R. Spiro,et al.  A prospective phase ii trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck , 1998, Head & neck.

[57]  A. Huang,et al.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.

[58]  T. Wendt,et al.  Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Hanauske,et al.  Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  L. Bastholt,et al.  A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[61]  M. Secic,et al.  Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer , 1997, Head & neck.

[62]  B. Kavanagh,et al.  Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation , 1997, Oncogene.

[63]  J. Quivey,et al.  Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. , 1997, International journal of radiation oncology, biology, physics.

[64]  L. Collette,et al.  Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. , 1996, Journal of the National Cancer Institute.

[65]  E. Strong,et al.  21 Long term results of primary radiation therapy for squamous cancer of the base of tongue , 1996 .

[66]  W. Curran,et al.  Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. , 1995, International journal of radiation oncology, biology, physics.

[67]  M. August,et al.  Early carcinoma of the oral cavity: a conservative approach with radiation therapy. , 1995, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[68]  L. Eapen,et al.  Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  M. Zelefsky,et al.  Performance status after treatment for squamous cell cancer of the base of tongue--a comparison of primary radiation therapy versus primary surgery. , 1994, International journal of radiation oncology, biology, physics.

[70]  S. Stringer,et al.  Carcinoma of the oral tongue: A comparison of results and complications of treatment with radiotherapy and/or surgery , 1994, Head & neck.

[71]  K. Valerie,et al.  Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. , 1994, International journal of radiation oncology, biology, physics.

[72]  M. Piccart,et al.  Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck , 1994 .

[73]  G. Browman,et al.  Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. , 1994, Seminars in oncology.

[74]  A. Paccagnella,et al.  Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. , 1994, Journal of the National Cancer Institute.

[75]  S. Stringer,et al.  Radiotherapy alone or combined with neck dissection for T1-T2 carcinoma of the pyriform sinus: an alternative to conservation surgery. , 1993, International journal of radiation oncology, biology, physics.

[76]  A. Forastiere Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. , 1993, Seminars in oncology.

[77]  R. Tsang,et al.  Squamous cell carcinoma of the lip: analysis of the Princess Margaret Hospital experience. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[78]  L. Hutchins,et al.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  N. Hayward,et al.  Analysis of gene amplification in head‐and‐neck squamous‐cell carcinomas , 1991, International journal of cancer.

[80]  W. Hong,et al.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. , 1991, The New England journal of medicine.

[81]  J E Medina,et al.  Standardizing neck dissection terminology. Official report of the Academy's Committee for Head and Neck Surgery and Oncology. , 1991, Archives of otolaryngology--head & neck surgery.

[82]  J. Crook,et al.  Effect of dose rate on local control and complications in definitive irradiation of T1-2 squamous cell carcinomas of mobile tongue and floor of mouth with interstitial iridium-192. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[83]  J. Crook,et al.  Iridium 192 implantation of T1 and T2 carcinomas of the mobile tongue. , 1990, International journal of radiation oncology, biology, physics.

[84]  L. Harrison,et al.  Prospective computer-assisted voice analysis for patients with early stage glottic cancer: a preliminary report of the functional result of laryngeal irradiation. , 1990, International journal of radiation oncology, biology, physics.

[85]  W. Fee,et al.  Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. A report from the northern California oncology group , 1987, Cancer.

[86]  F. Baillet,et al.  A retrospective study of three treatment techniques for T1-T2 base of tongue lesions: surgery plus postoperative radiation, external radiation plus interstitial implantation and external radiation alone. , 1987, International journal of radiation oncology, biology, physics.

[87]  W. Mendenhall,et al.  Carcinoma of the soft palate treated with irradiation: analysis of results and complications. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[88]  F. Demard,et al.  Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. , 1986, British Journal of Cancer.

[89]  J. Horiot,et al.  Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer. , 1986, International journal of radiation oncology, biology, physics.

[90]  J. Jacobs,et al.  Improved complete response rate and survival in advanced head and neck cancer after three‐course induction therapy with 120‐hour 5‐FU infusion and cisplatin , 1985, Cancer.

[91]  M. Hidalgo,et al.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[93]  E. Vokes,et al.  Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  J. Wilson,et al.  Cisplatinum and Bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial , 2004, Cancer Chemotherapy and Pharmacology.

[95]  M. al-Sarraf Chemotherapeutic management of head and neck cancer , 2004, Cancer and Metastasis Reviews.

[96]  J. Ensley,et al.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  A. Ullrich,et al.  Receptor tyrosine kinases as targets for anticancer drugs. , 2002, Trends in molecular medicine.

[98]  B. Burtness,et al.  Phase III trial comparing cisplatin (C) + placebo (P) + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC) , 2002 .

[99]  J. Baselga,et al.  ZD1839 ('Iressa') as an anticancer agent. , 2000, Drugs.

[100]  R Mohan,et al.  The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. , 2000, International journal of radiation oncology, biology, physics.

[101]  A. Garden,et al.  A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. , 2000, International journal of radiation oncology, biology, physics.

[102]  G. Calais,et al.  Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. , 1999, Journal of the National Cancer Institute.

[103]  Jay S. Cooper,et al.  A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 , 1999 .

[104]  G. Catimel Head and neck cancer: guidelines for chemotherapy. , 1996, Drugs.

[105]  S. Taylor Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[106]  Z. Petrovich,et al.  Carcinoma of the lip and selected sites of head and neck skin. A clinical study of 896 patients. , 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[107]  J. Medina,et al.  Treatment of choice for squamous carcinoma of the tonsillar fossa. , 1985, Head & neck surgery.